The novel coronavirus (COVID-19) pandemic is evolving rapidly and will have a significant impact on the global healthcare system. Many hospitals, regions and countries are updating their treatment guidelines and Ayala is taking necessary steps to fully comply with new guidance. Ayala’s primary obligation is to avoid unnecessary exposure in an at-risk population while maintaining study data integrity.
To our trial participants:
Treatment will continue for all patients currently enrolled in our clinical studies. As always, your health is our first concern. Together with your healthcare team, we will do everything possible to keep our trials open to participants, including making sure there is enough supply of the investigational drug available. If you are a patient in a clinical trial, it’s important to stay in close communication with your doctors and healthcare team to report any illness or side effects. In the event that you are unable to be seen at your treatment center for your regular visit, we will work closely with the clinical trial site to identify alterative options. If you have a question or requests, please contact us through firstname.lastname@example.org. We will make every effort to respond promptly.
To physicians requesting drug outside of a clinical trial:
We will continue to follow the procedures for gaining access to our investigational medicines as outlined on our website. During these unprecedented times, our obligation is first and foremost to those individuals currently enrolled in our clinical trials. If you have a question or requests, please contact us through EAP@ayalapharma.com. We will make every effort to respond promptly.
Ayala is currently evaluating AL101 in 2 ongoing Phase 2 trials:
Our ACCURACY trial for the treatment of patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC), and our Phase 2 TENACITY trial for the treatment of patients with Recurrent/Metastatic triple negative breast cancer (R/M TNBC).
Ayala is also currently evaluating AL102 in our Phase 2/3 RINGSIDE trial for the treatment of patients with progressing desmoid tumors. AL102 is also being evaluated in a Phase 1 trial in combination with Novartis’ BCMA targeting agent, WVT078, in patients with relapsed/refractory multiple myeloma (R/R MM).
Ayala is planning to initiate a Phase 2 trial of AL101 for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (R/R T-ALL).
As part of our commitment to advancing the treatment of rare cancers, we are conducting clinical trials of our investigational medicines to demonstrate their safety and efficacy in cancer patients. People who choose to participate in clinical trials play a critical role in developing new medicines.